Biosimilars: EU Payer Perspectives
Leading European payer experts reveal the real impact of biosimilars over the last 12 months
Keeping track of the dynamics and nuances of the biosimilars market is critical – not least because the $232 billion global biologics market is now seriously under threat. New biosimilar entrants have been taking on the European biologic brands for the last decade. The difference is: now they're winning.
Are you keeping up with the recent step change in the biologics marketplace?
Despite the best efforts of the doom-mongers, the clouds hanging over biosimilars have lifted. Payers, doctors and even patients are no longer wary. After nearly a decade, the positive experiences across Europe have multiplied; costs have plummeted; patients are switching; and treatment rates have steadily gone up. The penny has finally dropped: biosimilars are not a problem. So how will you respond?
What to expect from this report
Biosimilars: EU Payer Perspectives gives the inside track on the biosimilars market today, offering new information to help you stay ahead. For this report, we've spoken directly to 10 high-profile payer decision-makers and reimbursement influencers across Europe. These are the people who define and execute the formulary decisions and payer strategies that reverberate across the pharma landscape. What they think matters.
This 87-page report covers how the European market has changed over the last 12 months as well as offering expert payer views on current practice and what is likely to happen next. Key issues discussed include regulatory policy and frameworks, commercial tactics and pipeline launches.
'Aligned with evolving national policies, the commercial tactics employed by payers are becoming increasingly aggressive toward biosimilars. Tenders have become the go-to strategy being used by payers in Europe to ensure rapid adoption of biosimilars. A direct consequence of this is that price has become the only commercial lever that companies can pull in order to differentiate themselves from other companies, with other offerings (e.g. devices, patient support services, etc.) seen as minimally influential. National initiatives which 'gamify' biosimilar adoption rates have also been hugely successful.'
Example quote included in Biosimilars: EU Payer Perspectives
'There have been huge cost savings over the last two years, since infliximab, etanercept and MabThera biosimilars have reached the UK market. The rate of growth at the complex biologics end of the pharmaceuticals market has levelled off to a certain extent; we've gone from a 12-15 percent year-on-year increase in spending to a 2-3 percent increase in the last financial year and that's mainly due to the availability of biosimilars.'
The expert panel interviewed for Biosimilars: EU Payer Perspectives
Branded drug manufacturers must work harder to deliver value in order to compete successfully against biosimilars—and understanding what lies behind changing payer opinion is a key part of any successful strategy.
Why FirstWord reports are different
Branded drug manufacturers must work harder to deliver value in order to compete successfully against biosimilars—and understanding what lies behind changing payer opinion is a key part of any successful strategy.
Keeping track of the dynamics and nuances of the biosimilars market is critical – not least because the $232 billion global biologics market is now seriously under threat. New biosimilar entrants have been taking on the European biologic brands for the last decade. The difference is: now they're winning.
Are you keeping up with the recent step change in the biologics marketplace?
Despite the best efforts of the doom-mongers, the clouds hanging over biosimilars have lifted. Payers, doctors and even patients are no longer wary. After nearly a decade, the positive experiences across Europe have multiplied; costs have plummeted; patients are switching; and treatment rates have steadily gone up. The penny has finally dropped: biosimilars are not a problem. So how will you respond?
What to expect from this report
Biosimilars: EU Payer Perspectives gives the inside track on the biosimilars market today, offering new information to help you stay ahead. For this report, we've spoken directly to 10 high-profile payer decision-makers and reimbursement influencers across Europe. These are the people who define and execute the formulary decisions and payer strategies that reverberate across the pharma landscape. What they think matters.
This 87-page report covers how the European market has changed over the last 12 months as well as offering expert payer views on current practice and what is likely to happen next. Key issues discussed include regulatory policy and frameworks, commercial tactics and pipeline launches.
- 20 current issues of most interest to pharma were uncovered during preliminary research
- We used these to pose an average of 36 targeted questions of each expert
- Their responses provided 37 unique new insights
- Insights are supported by 242 directly quoted comments
- Key events in the European biosimilars market
- The demand and need for biosimilars education
- Delivering effective and tailored biosimilars education
- The value of local-level educational initiatives
- The European regulatory framework for biosimilars
- The evolution, challenges and opportunities with biosimilar switching
- Current views on the potential for pharmacy-level substitution
- The impact of biosimilars on the European prescribing environment
- European payer tactics used to drive biosimilar adoption
- Local initiatives and their influence on biosimilar adoption rates
- The evolution of payer and originator tactics in the future
- The impact of complex biosimilar launches in Europe
- Key challenges in the introduction of complex biosimilars
- Insights into the commercial strategies of biosimilar companies
- Uncovering the reasons behind the UK’s success in introducing biosimilars
- The success (or failure) of originator company biosimilar defence strategies
- Future adoption drivers of Remicade, Enbrel and MabThera biosimilars in Europe
- Opportunities and challenges in relation to Herceptin biosimilars
- Opportunities and challenges in relation to Humira biosimilars
- Future challenges and opportunities in the European biosimilars market
'Aligned with evolving national policies, the commercial tactics employed by payers are becoming increasingly aggressive toward biosimilars. Tenders have become the go-to strategy being used by payers in Europe to ensure rapid adoption of biosimilars. A direct consequence of this is that price has become the only commercial lever that companies can pull in order to differentiate themselves from other companies, with other offerings (e.g. devices, patient support services, etc.) seen as minimally influential. National initiatives which 'gamify' biosimilar adoption rates have also been hugely successful.'
Example quote included in Biosimilars: EU Payer Perspectives
'There have been huge cost savings over the last two years, since infliximab, etanercept and MabThera biosimilars have reached the UK market. The rate of growth at the complex biologics end of the pharmaceuticals market has levelled off to a certain extent; we've gone from a 12-15 percent year-on-year increase in spending to a 2-3 percent increase in the last financial year and that's mainly due to the availability of biosimilars.'
The expert panel interviewed for Biosimilars: EU Payer Perspectives
- Former Vice-Chair of the Economic Affairs Committee of LEEM; currently working as an independent consultant, France
- Former Research Director, scientific and technological institute within the French Ministry of Health; currently working as a consultant for a large regional payer, France
- Former member of the Transparency Committee, HAS; currently working as a senior member of a regional clinical research centre, France
- Head of Drug Reimbursement; large regional payer, Germany
- Associate Member of the Drug Commission of the German Medical Association, Germany
- Full Member of the Drug Commission of the German Medical Association, Germany
- Chief Pharmacist; cancer specialist hospital, South East England, UK
- Clinical Director, Pharmacy and Prescribing; pricing and reimbursement organisation, UK
- Specialist Procurement Pharmacist; large NHS Trust, North East England, UK
- Senior leadership team member, Spanish Association of Biosimilars (BioSim), Spain
Branded drug manufacturers must work harder to deliver value in order to compete successfully against biosimilars—and understanding what lies behind changing payer opinion is a key part of any successful strategy.
Why FirstWord reports are different
Branded drug manufacturers must work harder to deliver value in order to compete successfully against biosimilars—and understanding what lies behind changing payer opinion is a key part of any successful strategy.
- Hand-picked panel of experts: For every report, we take time to identify and approach those individuals with the most relevant experience at a senior level who can genuinely be regarded as experts in their field.
- Entirely new information: Because our reports are based on interviews conducted in the last few weeks, the insights and analysis are fresh and new. This is a perspective you simply can't source anywhere else.
- Driven by the needs of pharma: Our professional researchers and writers are industry specialists who are proficient at delving into the detail and discovering answers to the key questions pharma needs to ask.
1. SUBJECT SYNOPSIS
1.1 Sources
2. RESEARCH METHODOLOGY AND OBJECTIVES
2.1 Methodology
2.2 Objectives
2. KEY INSIGHTS SUMMARY
3. ISSUES AND INSIGHTS
3.1 Key events in the European biosimilars market
3.1.1 Issue summary
3.1.2 Questions
3.1.3 Key insights
3.1.4 Supporting quotes
3.1.5 Intelligence exhibits
3.1.6 Sources
4. THE DEMAND AND NEED FOR BIOSIMILARS EDUCATION
4.1 Issue summary
4.2 Questions
4.3 Key insights
4.4 Supporting quotes
4.5 Sources
5. DELIVERING EFFECTIVE AND TAILORED BIOSIMILARS EDUCATION
5.1 Issue summary
5.2 Questions
5.3 Key insights
5.4 Supporting quotes
5.5 Sources
6. THE VALUE OF LOCAL-LEVEL EDUCATIONAL INITIATIVES
6.1 Issue summary
6.2 Questions
6.3 Key insights
6.4 Supporting quotes
6.5 Intelligence exhibits
6.6 Sources
7. THE EUROPEAN REGULATORY FRAMEWORK FOR BIOSIMILARS
7.1 Issue summary
7.2 Questions
7.3 Key insights
7.4 Supporting quotes
7.5 Sources
8. THE EVOLUTION, CHALLENGES AND OPPORTUNITIES WITH BIOSIMILAR SWITCHING
8.1 Issue summary
8.2 Questions
8.3 Key insights
8.4 Supporting quotes
8.5 Sources
9. CURRENT VIEWS ON THE POTENTIAL FOR PHARMACY-LEVEL SUBSTITUTION
9.1 Issue summary
9.2 Questions
9.3 Key insights
9.4 Supporting quotes
9.5 Sources
10. THE IMPACT OF BIOSIMILARS ON THE EUROPEAN PRESCRIBING ENVIRONMENT
10.1 Issue summary
10.2 Questions
10.3 Key insights
10.4 Support quote
10.5 Sources
11. EUROPEAN PAYER TACTICS USED TO DRIVE BIOSIMILAR ADOPTION
11.1 Issue summary
11.2 Questions
11.3 Key insights
11.4 Supporting quotes
11.5 Sources
12. LOCAL INITIATIVES AND THEIR INFLUENCE ON BIOSIMILAR ADOPTION RATES
12.1 Issue summary
12.2 Questions
12.3 Key insights
12.4 Supporting quotes
12.5 Sources
13. THE EVOLUTION OF PAYER AND ORIGINATOR TACTICS IN THE FUTURE
13.1 Issue summary
13.2 Questions
13.3 Key insights
13.4 Supporting quotes
13.5 Sources
14. THE IMPACT OF COMPLEX BIOSIMILAR LAUNCHES IN EUROPE
14.1 Issue summary
14.2 Questions
14.3 Key insights
14.4 Supporting quotes
14.5 Sources
15. KEY CHALLENGES IN THE INTRODUCTION OF COMPLEX BIOSIMILARS
15.1 Issue summary
15.2 Questions
15.3 Key insights
15.4 Supporting quotes
15.5 Sources
16. INSIGHTS INTO THE COMMERCIAL STRATEGIES OF BIOSIMILAR COMPANIES
16.1 Issue summary
16.2 Questions
16.3 Key insights
16.4 Supporting quotes
16.5 Sources
17. UNCOVERING THE REASONS BEHIND THE UK’S SUCCESS IN INTRODUCING BIOSIMILARS
17.1 Issue summary
17.2 Questions
17.3 Key insights
17.4 Supporting quotes
17.5 Sources
18. THE SUCCESS (OR FAILURE) OF ORIGINATOR COMPANY BIOSIMILAR DEFENCE STRATEGIES
18.1 Issue summary
18.2 Questions
18.3 Key insights
18.4 Supporting quotes
18.5 Sources
19. FUTURE ADOPTION DRIVERS OF REMICADE, ENBREL AND MABTHERA BIOSIMILARS IN EUROPE
19.1 Issue summary
19.2 Questions
19.3 Key insights
19.4 Supporting quotes
19.5 Sources
20. OPPORTUNITIES AND CHALLENGES IN RELATION TO HERCEPTIN BIOSIMILARS
20.1 Issue summary
20.2 Questions
20.3 Key insights
20.4 Support quotes
20.5 Sources
21. OPPORTUNITIES AND CHALLENGES IN RELATION TO HUMIRA BIOSIMILARS
21.1 Summary
21.2 Questions
21.3 Key insights.
21.4 Supporting quotes
21.5 Sources
22. FUTURE CHALLENGES AND OPPORTUNITIES IN THE EUROPEAN BIOSIMILARS MARKET
1. SUMMARY
2. QUESTIONS
3. KEY INSIGHTS
4. SUPPORTING QUOTES
5. SOURCES
1.1 Sources
2. RESEARCH METHODOLOGY AND OBJECTIVES
2.1 Methodology
2.2 Objectives
2. KEY INSIGHTS SUMMARY
3. ISSUES AND INSIGHTS
3.1 Key events in the European biosimilars market
3.1.1 Issue summary
3.1.2 Questions
3.1.3 Key insights
3.1.4 Supporting quotes
3.1.5 Intelligence exhibits
3.1.6 Sources
4. THE DEMAND AND NEED FOR BIOSIMILARS EDUCATION
4.1 Issue summary
4.2 Questions
4.3 Key insights
4.4 Supporting quotes
4.5 Sources
5. DELIVERING EFFECTIVE AND TAILORED BIOSIMILARS EDUCATION
5.1 Issue summary
5.2 Questions
5.3 Key insights
5.4 Supporting quotes
5.5 Sources
6. THE VALUE OF LOCAL-LEVEL EDUCATIONAL INITIATIVES
6.1 Issue summary
6.2 Questions
6.3 Key insights
6.4 Supporting quotes
6.5 Intelligence exhibits
6.6 Sources
7. THE EUROPEAN REGULATORY FRAMEWORK FOR BIOSIMILARS
7.1 Issue summary
7.2 Questions
7.3 Key insights
7.4 Supporting quotes
7.5 Sources
8. THE EVOLUTION, CHALLENGES AND OPPORTUNITIES WITH BIOSIMILAR SWITCHING
8.1 Issue summary
8.2 Questions
8.3 Key insights
8.4 Supporting quotes
8.5 Sources
9. CURRENT VIEWS ON THE POTENTIAL FOR PHARMACY-LEVEL SUBSTITUTION
9.1 Issue summary
9.2 Questions
9.3 Key insights
9.4 Supporting quotes
9.5 Sources
10. THE IMPACT OF BIOSIMILARS ON THE EUROPEAN PRESCRIBING ENVIRONMENT
10.1 Issue summary
10.2 Questions
10.3 Key insights
10.4 Support quote
10.5 Sources
11. EUROPEAN PAYER TACTICS USED TO DRIVE BIOSIMILAR ADOPTION
11.1 Issue summary
11.2 Questions
11.3 Key insights
11.4 Supporting quotes
11.5 Sources
12. LOCAL INITIATIVES AND THEIR INFLUENCE ON BIOSIMILAR ADOPTION RATES
12.1 Issue summary
12.2 Questions
12.3 Key insights
12.4 Supporting quotes
12.5 Sources
13. THE EVOLUTION OF PAYER AND ORIGINATOR TACTICS IN THE FUTURE
13.1 Issue summary
13.2 Questions
13.3 Key insights
13.4 Supporting quotes
13.5 Sources
14. THE IMPACT OF COMPLEX BIOSIMILAR LAUNCHES IN EUROPE
14.1 Issue summary
14.2 Questions
14.3 Key insights
14.4 Supporting quotes
14.5 Sources
15. KEY CHALLENGES IN THE INTRODUCTION OF COMPLEX BIOSIMILARS
15.1 Issue summary
15.2 Questions
15.3 Key insights
15.4 Supporting quotes
15.5 Sources
16. INSIGHTS INTO THE COMMERCIAL STRATEGIES OF BIOSIMILAR COMPANIES
16.1 Issue summary
16.2 Questions
16.3 Key insights
16.4 Supporting quotes
16.5 Sources
17. UNCOVERING THE REASONS BEHIND THE UK’S SUCCESS IN INTRODUCING BIOSIMILARS
17.1 Issue summary
17.2 Questions
17.3 Key insights
17.4 Supporting quotes
17.5 Sources
18. THE SUCCESS (OR FAILURE) OF ORIGINATOR COMPANY BIOSIMILAR DEFENCE STRATEGIES
18.1 Issue summary
18.2 Questions
18.3 Key insights
18.4 Supporting quotes
18.5 Sources
19. FUTURE ADOPTION DRIVERS OF REMICADE, ENBREL AND MABTHERA BIOSIMILARS IN EUROPE
19.1 Issue summary
19.2 Questions
19.3 Key insights
19.4 Supporting quotes
19.5 Sources
20. OPPORTUNITIES AND CHALLENGES IN RELATION TO HERCEPTIN BIOSIMILARS
20.1 Issue summary
20.2 Questions
20.3 Key insights
20.4 Support quotes
20.5 Sources
21. OPPORTUNITIES AND CHALLENGES IN RELATION TO HUMIRA BIOSIMILARS
21.1 Summary
21.2 Questions
21.3 Key insights.
21.4 Supporting quotes
21.5 Sources
22. FUTURE CHALLENGES AND OPPORTUNITIES IN THE EUROPEAN BIOSIMILARS MARKET
1. SUMMARY
2. QUESTIONS
3. KEY INSIGHTS
4. SUPPORTING QUOTES
5. SOURCES
